首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL-1 |
| Uniprot No | P01584 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 117-269aa |
| 氨基酸序列 | APVRSLNCTL RDSQQKSLVM SGPYELKALH LQGQDMEQQV VFSMSFVQGE ESNDKIPVAL GLKEKNLYLS CVLKDDKPTL QLESVDPKNY PKKKMEKRFV FNKIEINNKL EFESAQFPNW YISTSQAENM PVFLGGTKGG QDITDFTMQF VSS |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-1重组蛋白的经典参考文献及其摘要概述：
---
1. **文献名称**: *Cloning and expression of interleukin-1β in Escherichia coli*
**作者**: Auron, P.E., et al.
**摘要**: 该研究首次报道了人IL-1β基因的克隆及其在大肠杆菌中的重组表达，证实重组IL-1β具有与天然蛋白相似的生物活性，为后续炎症机制研究提供工具。
2. **文献名称**: *Recombinant human interleukin-1 receptor antagonist (IL-1Ra) in inflammatory diseases*
**作者**: Dinarello, C.A.
**摘要**: 探讨重组IL-1受体拮抗剂(IL-1Ra)的临床应用，证明其通过阻断IL-1信号通路显著减轻类风湿关节炎等自身免疫性疾病的炎症反应。
3. **文献名称**: *Crystal structure of recombinant human interleukin-1β at 2.0 Å resolution*
**作者**: Priestle, J.P., et al.
**摘要**: 通过X射线晶体学解析重组人IL-1β的三维结构，揭示了其与受体结合的分子机制，为设计靶向IL-1信号的小分子药物奠定结构基础。
---
**备注**：以上文献发表于1980-1990年代，属于IL-1研究的奠基性工作。如需近年研究(如IL-1重组蛋白在肿瘤免疫或新冠炎症中的应用)，建议补充具体研究领域。
Interleukin-1 (IL-1) is a pro-inflammatory cytokine that plays a central role in regulating immune and inflammatory responses. The IL-1 family comprises two primary agonistic isoforms, IL-1α and IL-1β, with IL-1β being the most studied due to its critical involvement in innate immunity, fever, sepsis, and autoimmune diseases. Both isoforms bind to the IL-1 receptor (IL-1R), triggering downstream signaling pathways such as NF-κB and MAPK, which amplify inflammatory cascades. Dysregulation of IL-1 signaling is implicated in chronic inflammatory conditions like rheumatoid arthritis, gout, and inflammatory bowel disease.
Recombinant IL-1 proteins, produced using recombinant DNA technology, are essential tools for studying IL-1 biology and developing therapeutic interventions. These proteins are typically expressed in bacterial systems (e.g., E. coli) or mammalian cell lines to ensure proper folding and post-translational modifications. Recombinant IL-1β, for instance, is widely used in preclinical research to model inflammation, test anti-inflammatory drugs, and explore mechanisms of cytokine storms. Conversely, recombinant IL-1 receptor antagonist (IL-1Ra), such as the FDA-approved drug Anakinra, acts as a competitive inhibitor of IL-1R, demonstrating the therapeutic potential of modulating IL-1 pathways.
Beyond therapeutics, recombinant IL-1 proteins serve as standards in immunoassays, enabling precise quantification of IL-1 levels in clinical samples. They also facilitate structural studies to design targeted inhibitors. Despite their utility, challenges remain in minimizing endotoxin contamination during production and optimizing bioactivity for specific applications. Overall, recombinant IL-1 proteins continue to bridge basic research and clinical innovation, offering insights into immune regulation and advancing treatments for inflammation-driven diseases.
×
